Literature DB >> 25847730

Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients.

Fernando Bril1,2, Carolina Ortiz-Lopez3, Romina Lomonaco1,2, Beverly Orsak3, Michael Freckleton4, Kedar Chintapalli4, Jean Hardies4, Song Lai5, Felipe Solano6, Fermin Tio6, Kenneth Cusi1,2,3,7.   

Abstract

BACKGROUND & AIMS: Liver ultrasound (US) is usually used in the clinical setting for the diagnosis and follow-up of patients with nonalcoholic fatty liver disease (NAFLD). However, no large study has carefully assessed its performance using a semiquantitative ultrasonographic scoring system in overweight/obese patients, in comparison to magnetic resonance spectroscopy ((1) H-MRS) and histology.
METHODS: We recruited 146 patients and performed: a liver US using a 5-parameter scoring system, a liver (1) H-MRS to quantify liver fat content, and a liver biopsy to assess histology. All measurements were repeated in a subgroup of patients (n = 62) after 18 months of follow-up.
RESULTS: The performance of liver US (parenchymal echo alone) was rather modest, and significantly worse than (1) H-MRS (AUROC: 0.82 [0.69-0.94] vs. 0.96 [0.90-1.00]; P = 0.04). However, the AUROC improved when different echographic parameters were taken into account (AUROC: 0.89 [0.83-0.96], P = 0.15 against (1) H-MRS). Optimum sensitivity for liver US was achieved at a liver fat content ≥12.5%, suggesting that below this threshold, liver US is less sensitive. Liver (1) H-MRS showed a high accuracy for the diagnosis of NAFLD, and correlated strongly with histological steatosis (r = 0.73, P < 0.0001). None of the imaging tests was adequate enough to predict changes over time in histology.
CONCLUSIONS: Despite its widespread use, liver US has several important limitations that healthcare providers should recognize, particularly because of its low sensitivity. Using a combination of echographic parameters, liver US showed a significant improvement in its diagnostic performance, but still was of limited value for monitoring treatment over time.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  NAFLD; NASH; Obesity; hepatic steatosis; steatohepatitis

Mesh:

Year:  2015        PMID: 25847730     DOI: 10.1111/liv.12840

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  40 in total

1.  Indications of Liver Biopsy in the Era of Noninvasive Assessment of Liver Fibrosis.

Authors:  Deepak Amarapurkar; Anjali Amarapurkar
Journal:  J Clin Exp Hepatol       Date:  2015-10-23

2.  Non-alcoholic fatty liver disease in the first trimester and subsequent development of gestational diabetes mellitus.

Authors:  Seung Mi Lee; Soo Heon Kwak; Ja Nam Koo; Ig Hwan Oh; Jeong Eun Kwon; Byoung Jae Kim; Sun Min Kim; Sang Youn Kim; Gyoung Min Kim; Sae Kyung Joo; Bo Kyung Koo; Sue Shin; Chanthalakeo Vixay; Errol R Norwitz; Chan-Wook Park; Jong Kwan Jun; Won Kim; Joong Shin Park
Journal:  Diabetologia       Date:  2018-11-23       Impact factor: 10.122

3.  Ultrasound and FibroScan® Controlled Attenuation Parameter in patients with MAFLD: head to head comparison in assessing liver steatosis.

Authors:  Andrea Salmi; Luigi di Filippo; Clarissa Ferrari; Stefano Frara; Andrea Giustina
Journal:  Endocrine       Date:  2022-08-18       Impact factor: 3.925

4.  Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease.

Authors:  Diana Barb; Enrico M Repetto; Michael E Stokes; Sudha S Shankar; Kenneth Cusi
Journal:  Obesity (Silver Spring)       Date:  2021-09-23       Impact factor: 9.298

Review 5.  Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging.

Authors:  Yingzhen N Zhang; Kathryn J Fowler; Gavin Hamilton; Jennifer Y Cui; Ethan Z Sy; Michelle Balanay; Jonathan C Hooker; Nikolaus Szeverenyi; Claude B Sirlin
Journal:  Br J Radiol       Date:  2018-06-06       Impact factor: 3.039

6.  Radiographic Improvement of Hepatic Steatosis After Laparoscopic Roux-en-Y Gastric Bypass.

Authors:  Joshua S Winder; Brandon S Dudeck; Sarayna Schock; Jerome R Lyn-Sue; Randy S Haluck; Ann M Rogers
Journal:  Obes Surg       Date:  2017-02       Impact factor: 4.129

7.  Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes.

Authors:  Diana Barb; Fernando Bril; Srilaxmi Kalavalapalli; Kenneth Cusi
Journal:  J Clin Endocrinol Metab       Date:  2019-08-01       Impact factor: 5.958

8.  Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.

Authors:  Fernando Bril; Paola Portillo Sanchez; Romina Lomonaco; Beverly Orsak; Joan Hecht; Fermin Tio; Kenneth Cusi
Journal:  J Clin Endocrinol Metab       Date:  2017-08-01       Impact factor: 5.958

9.  Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV-HIV Co-infected Adults.

Authors:  Richard K Sterling; Wendy C King; Mandana Khalili; David E Kleiner; Amanda S Hinerman; Mark Sulkowski; Raymond T Chung; Mamta K Jain; M Auricio Lisker-Melman; David K Wong; Marc G Ghany
Journal:  Dig Dis Sci       Date:  2021-02-08       Impact factor: 3.487

10.  Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes.

Authors:  Kristin Alexandra Dayton; Fernando Bril; Diana Barb; Jinping Lai; Srilaxmi Kalavalapalli; Kenneth Cusi
Journal:  PLoS One       Date:  2021-06-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.